YOUR BUSINESS AUTHORITY
Springfield, MO
Pharmaceutical company Novo Nordisk missed analysts' expectations for the second quarter as its Wegovy and Ozempic GLP-1 drugs faced increasing competition.
Revenue in the second quarter was roughly $11.92 billion, short of expectations of $11.97 billion.
Earnings per share came to $5.96. Analysts were looking for $6.06 per share.
Read more from Quartz.
Organizers hope to bolster client traffic to center city businesses.
SBJ announces executive newsroom hires
Timeshare exit company owner sentenced for tax evasion
State awards Springfield $4.6M for wastewater system improvements
Stockton district names next superintendent
Trump, fast-food companies among targets of X redirects
Council modifies data center definitions bill, extends moratorium into next year